Search
fosdenopterin; cyclic pyranopterin monophosphate; cPMP (Nulibry)
Indications:
- treatment of molybdenum cofactor deficiency type A
Dosage:
- 9.5 mg injection
Adverse effects:
- complications related to the intravenous line
- fever, respiratory infections
- vomiting, gastroenteritis & diarrhea
- photosensitivity in animals
Mechanism of action:
- replaces missing cyclic pyranopterin monophosphate in individuals with rare genetic disorder
General
cofactor
metabolic agent (metabolic modifier)
Database Correlations
PUBCHEM correlations
References
- Wikipedia: Fosdenopterin
https://en.wikipedia.org/wiki/Fosdenopterin
- FDA News Release. Feb 26, 2021
FDA Approves First Treatment for Molybdenum Cofactor Deficiency Type A.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-molybdenum-cofactor-deficiency-type